FIIs Increase Stake in this Mukul Agrawal-Backed Company; Stock Hits All-Time High
Join Us
Follow Us
Neuland Laboratories Ltd shares climbed over 4 per cent as FIIs raised their stake ahead of Q1 results, while the company also approved a final dividend and expanded manufacturing capacity.
✨ Key Takeaways
Neuland Laboratories share price gained more than 4 per cent during Intraday trade on Wednesday, August 5, 2026, after the company held its Annual General Meeting (AGM) on August 4, 2026. Investor sentiment was also supported by an increase in foreign institutional investor (FII) shareholding and recent capacity expansion.
Share Price Hits All-Time High
The stock closed at Rs 19,956, up Rs 683, or 3.54 per cent, compared with its previous closing price of Rs 19,273. During the session, the stock touched an all-time high of Rs 20,100, representing a gain of around 4.29 per cent against its previous close.
Shareholders Approve Final Dividend
At the AGM, shareholders approved a final dividend of Rs 34 per equity share of face value Rs 10 each for the financial year ended March 31, 2026, as recommended by the Board of Directors.
Commercial Production Begins in Telangana
Earlier, on July 31, 2026, the company announced the commencement of commercial production at its expanded manufacturing facilities located at Bonthapally and Gaddapotharam in Telangana. The additional capacities have been commissioned under the company's ongoing expansion programme and are expected to strengthen its manufacturing capabilities.
Q1 FY27 Results in Focus
Investors are also awaiting the company's financial performance for the June quarter. Neuland Laboratories Ltd is scheduled to announce its Q1 FY27 results later today, with the earnings conference call set for 5:30 pm IST.
Also Read - Data Centre Stock Hits 10% Upper Circuit After Securing Rs 10.71 Crore Power Grid Order; Share Price Crosses Rs 1,000 Mark
FIIs Raise Holding
Foreign institutional investors increased their stake in Neuland Laboratories Ltd during the June quarter. Their shareholding rose from 20.46 per cent as on March 31, 2026, to 21.08 per cent as on June 30, 2026.
Ace Investor Mukul Agrawal continued to hold a 3.12 per cent stake in the company as of June 30, 2026.
About Neuland Laboratories Ltd
Established in 1984, Neuland Laboratories Ltd has over four decades of experience in active pharmaceutical ingredient (API) manufacturing and development. The company operates across two key business segments: Generic APIs and Contract Development and Manufacturing Organisation (CDMO) services.
It has a total reactor capacity of 12,26,000 litres and offers more than 100 APIs across 10 therapeutic areas. Export markets contribute nearly 90 per cent of the company's revenue, making it a globally focused pharmaceutical manufacturer.
Disclaimer: The article is for informational purposes only and not investment advice.